=> s gambogat?

L1 5 GAMBOGAT?

=> d 11 105

5 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE The answer numbers requested are not in the answer set. ENTER ANSWER NUMBER OR RANGE (1):1-5

- L1 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 857500-90-4 REGISTRY
- ED Entered STN: 28 Jul 2005
- CN 2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-71,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl)-7,2-(dimethylamino)ethyl ester, (22)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Butenoic acid, 2-methyl-4-[(1R,3as,5s,11R,14as)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-,2-(dimethylamino)ethyl ester, (22)- (9C1)

OTHER NAMES:

- CN 2-(Dimethylamino)ethyl gambogate
- FS STEREOSEARCH
- MF C42 H53 N O8
- SR CA
- LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L1 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 857500-60-8 REGISTRY
- ED Entered STN: 28 Jul 2005
- CN 2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,1H-furo[3,4-g]pyrano[3,2-b]yanthen-1-

yl]-, 2-(4-morpholinyl)ethyl ester, (2Z)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

2-Butenoic acid, 2-methy1-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-y1]-, 2-(4-morpholinyl)ethyl ester, (2Z)- (9CI)

OTHER NAMES:

CN 2-(Morpholin-4-vl)ethyl gambogate

STEREOSEARCH

MF C44 H55 N O9

SR

CA LC

STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry. Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN

RN 849665-76-5 REGISTRY

ED Entered STN: 03 May 2005

CN Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester(2Z)-compd. with

2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8,9-dihydroxy-3,3,11trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15dioxo-1,5-methano-1H,3H,11H-furo[3,4-q]pyrano[3,2-b]xanthen-1-y1]-2butenoic acid (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester,

mono[(2Z)-2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8,9dihydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3pentenv1)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-

1-v11-2-butenoatel (9CI)

OTHER NAMES:

CN Procaine neogambogate

STEREOSEARCH

ME C38 H44 O9 . C13 H20 N2 O2 SR

LC STN Files: CA, CAPLUS, TOXCENTER CM 1

CRN 849665-75-4 CMF C38 H44 O9

Absolute stereochemistry. Double bond geometry as shown.

CM

CRN 59-46-1 CMF C13 H20 N2 O2

- 1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- ANSWER 4 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 5914-82-9 REGISTRY
- ED Entered STN: 16 Nov 1984
- CN 2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8hydroxy-3, 3, 11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-y1)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1yl]-, methyl ester, (2Z)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

- CN 2-Butenoic acid, 2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, methyl ester, (2Z)- (9CI)
- Gambogic acid, methyl ester (7CI, 8CI) CN
- OTHER NAMES:

L1

- Methyl gambogate CN
- STEREOSEARCH
- DR 47866-09-1
- C39 H46 O8 ME

CI COM LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

11 REFERENCES IN FILE CA (1907 TO DATE) 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

- ANSWER 5 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 2631-91-6 REGISTRY
- ED Entered STN: 16 Nov 1984
- CN 2-Butenoic acid, 2-methvl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-y1]-, (2Z)-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES:
- CN 1,5-Methano-1H,3H,11H-furo[3,4-q]pyrano[3,2-b]xanthene-1-crotonic acid, 3a, 4, 5, 7-tetrahydro-8-hydroxy-a, 3, 3, 11-tetramethyl-13-(3-methyl-2butenvl)-11-(4-methvl-3-pentenvl)-7,15-dioxo-, (Z)-, compd. with pyridine (1:1) (8CI)
- CN Gambogic acid, compd. with pyridine (7CI)
- CN Pyridine, compd. with gambogic acid (1:1)
- OTHER NAMES: CN
- Pyridinium gambogate
- FS STEREOSEARCH
- MF C38 H44 O8 . C5 H5 N
- CA, CAPLUS, CASREACT, IMSRESEARCH, MRCK\*, TOXCENTER, USPAT2, LC STN Files: USPATFULL

(\*File contains numerically searchable property data)

CM 1

CRN 2752-65-0

CMF C38 H44 O8

CM 2

CRN 110-86-1 CMF C5 H5 N



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

8 REFERENCES IN FILE CA (1907 TO DATE)

8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s gambogam?

L4 5 GAMBOGAM?

=> d 14 1-5

- L4 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 905560-79-4 REGISTRY
- ED Entered STN: 31 Aug 2006
- CN 2-Butenamide, N-(2-ethoxyethyl)-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7,10,11-hexahydro-8,9-dihydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,9H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-methyl-, (2Z)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Butenamide, N-(2-ethoxyethyl)-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7,10,11-hexahydro-8,9-dihydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,9H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-methyl-, (2Z)-(9CI)

## OTHER NAMES:

- CN N-(2-Ethoxyethyl)neogambogamide
- CN NG-18 FS STEREOSEARCH
- FS STEREOSEARCH MF C42 H55 N O9
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

- L4 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 857501-29-2 REGISTRY
- ED Entered STN: 28 Jul 2005
- CN L-Aspartic acid, N-[(22)-2-methyl-1-oxo-4-[(1R,3a5,55,11R,14a5)-3a,4,5,7tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4g]pyrano[3,2-b]xanthen-1-yl]-2-buten-1-yl]- (CA INDEX NAME)
  OTHER CA INDEX NAME)

## OTHER NAMES:

- CN N-[(S)-1,2-Dicarboxyethyl]gambogamide
- FS STEREOSEARCH
- MF C42 H49 N O11
- SR CA
- LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

- L4 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 857501-27-0 REGISTRY
- ED Entered STN: 28 Jul 2005
- CN 2-Butenamide, N-[(4-azido-2,3,5,6-tetrafluorophenyl)methyl]-2-methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dloxo-1,5-methano-1H,3H,11H-furo[3,4-9]pyrano[3,2-b]xanthen-1-yl]-, (2Z)- (CA INDEX NAME) OTHER CA INDEX NAME;
- CN 2-Butenamide, N-[(4-azido-2,3,5,6-tetrafluorophenyl)methyl]-2-methyl-4-[(1R,3a5,55,11R,14a5)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3
  - methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-q]ovrano[3,2-b]xanthen-1-v]-, (2Z)- (9CI)
- OTHER NAMES:
- CN N-(4-Azido-2,3,5,6-tetrafluorobenzyl)gambogamide
- FS STEREOSEARCH
- MF C45 H46 F4 N4 O7
- SR CA
- LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

\_ N3

F

- 1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- ANSWER 4 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN L4
- RN 857500-92-6 REGISTRY
- ED Entered STN: 28 Jul 2005
- CN 2-Butenamide, 2-methyl-N-[3-(4-morpholinyl)propyl]-4-[(1R,3aS,5S,11R,14aS)-3a, 4, 5, 7-tetrahydro-8-hydroxy-3, 3, 11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo(3,4g]pyrano[3,2-b]xanthen-1-y1]-, (2Z)- (CA INDEX NAME)
- OTHER CA INDEX NAMES:
  - 2-Butenamide, 2-methyl-N-[3-(4-morpholinyl)propyl]-4-[(1R,3aS,5S,11R,14aS)-3a, 4, 5, 7-tetrahydro-8-hydroxy-3, 3, 11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo(3,4g]pyrano[3,2-b]xanthen-1-y1]-, (2Z)- (9CI)
- OTHER NAMES:
- CN N-[3-(Morpholin-4-yl)propyl]gambogamide
- FS STEREOSEARCH
- MF C45 H58 N2 O8
- ĊA SR
- LĊ STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1.4 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN

RN 857500-91-5 REGISTRY

ED Entered STN: 28 Jul 2005

2-Butenamide, 2-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-CN

[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3methy1-2-buten-1-y1)-11-(4-methy1-3-penten-1-y1)-7,15-dioxo-1,5-methano-1H.3H.11H-furo[3,4-q]pyrano[3,2-b]xanthen-1-v1]-, (2Z)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

2-Butenamide, 2-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-CN [(1R, 3aS, 5S, 11R, 14aS)-3a, 4, 5, 7-tetrahydro-8-hydroxy-3, 3, 11-trimethyl-13-(3methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H, 3H, 11H-furo[3, 4-q]pyrano[3, 2-b]xanthen-1-y1]-, (2Z)- (9CI)

OTHER NAMES:

CN N-[3-(4-Methylpiperazin-1-yl)propyl]gambogamide

STEREOSEARCH FS C46 H61 N3 O7

MF

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

> s 14 L5 3 L4

=> d 15 1-3 ibib abs hitstr

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1088055 CAPLUS <<LOGINID::20090326>>

DOCUMENT NUMBER: 149:323145

TITLE: Caspase-8 preferentially senses the aplptosis-inducing

action of NG-18, a gambogic acid derivative, in human

leukemia HL-60 cells

AUTHOR(S): Tao, Zhijian; Zhou, Yunlong; Lu, Jinjian; Duan, Wenhu; Qin, Yuxin; He, Xinxia; Lin, Liping; Ding, Jian

CORPORATE SOURCE: College of Chemistry and Life, Thejiang Normal University, Jinhua Zhejiang, Peop. Rep. China

SOURCE: Cancer Biology & Therapy (2007), 6(5), 691-696

CODEN: CBTAAO; ISSN: 1538-4047
UBLISHER: Landes Bioscience

PUBLISHER: Landes Biosci
DOCUMENT TYPE: Journal

LANGUAGE: English

Gambogic acid (GA) is the major active ingredient of gamboge secreted from a Chinese traditional medicine Garcinia hanburryi possessing potent anti-tumor activity. N-(2-ethoxyethyl)neogambogamide (NG-18), a derivative of GA, also efficiently inhibits proliferation of cultured human tumor cells. The inhibition effect of NG-18 is associated with its ability to induce apoptosis. In the present study, NG-18 markedly induced leukemia HL-60 cells apoptosis, and the extrinsic and intrinsic apoptosis pathways were activated almost at the same time. NG-18-induced tumor cell apoptosis was associated with up-regulation of pro-apoptotic Bcl-2 family member Bax, and downregulation of anti-apoptotic protein Bc1-2. The NG-18-induced apoptosis was blocked completely by a pan-caspase inhibitor Z-VAD-FMK, indicating that caspases were functionally and actively involved in this process. The specific inhibition of caspase-8 activity using Z-IETD-FMK significantly blocked NG-18-induced apoptosis. In contrast, inhibition of other initiator caspases, caspase-2 or -9, using Z-VDVAD-FMK or Z-LEHD-FMK resp. had no effect on NG-18-induced apoptosis. Altogether, the authors' data demonstrated that NG-18-induced apoptosis was dependent on caspases and caspase-8 acted as a key executor in the event.

T 905560-79-4, N-(2-Ethoxyethyl)neogambogamide

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NG-18; gambogic acid derivative N-(2-ethoxyethyl)neogambogamide showed anticancer activity, induced extrinsic and intrinsic apoptosis pathway preferentially mediated by caspase-8 in human leukemia cell)

RN

CN 2-Butenamide, N-(2-ethoxyethyl)-4-[(1R, 3aS, 5S, 11R, 14aS)-3a, 4, 5, 7, 10, 11hexahydro-8,9-dihydroxy-3,3,11-trimethy1-13-(3-methy1-2-buten-1-y1)-11-(4methy1-3-penten-1-y1)-7,15-dioxo-1,5-methano-1H,3H,9H-furo[3,4g]pyrano[3,2-b]xanthen-1-y1]-2-methy1-, (2Z)- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown. Currently available stereo shown.

REFERENCE COUNT: THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

2006:459169 CAPLUS <<LOGINID::20090326>> ACCESSION NUMBER:

DOCUMENT NUMBER: 145:230466

TITLE: Neogambogic acid derivatives used to treat cancer, and

preparation thereof

Duan, Wenhu; Zhou, Yunlong; Jiang, Hualiang; Ding, Jian; Luo, Xiaomin; Chen, Yi

PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Chinese Academy

of Sciences, Peop. Rep. China SOURCE: Faming Zhuanli Shenging Gongkai Shuomingshu, 37 pp.

CODEN: CNXXEV Patent


DOCUMENT TYPE: LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

INVENTOR(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
CN 1715283 PRIORITY APPLN. INFO.:	A	20060104	CN 2004-10025719 CN 2004-10025719	20040702 20040702	
OTHER SOURCE(S):	MARPAT	145:230466			



The title Gambogic acid derivs. have general formula I (R3 = H, C1-10 AR alkyl-substituted or aryl-substituted acyl; R2 = H, linear or branched C1-10 alkyl, C3-8 cycloalkyl, aryl or aryl substituted with C1-10 alkyl, heteroaryl, C1-10 alkyl-substituted or aryl-substituted acyl; X2 = carbonyl oxygen atom or hydroxyl; R13 = linear or branched C1-10 alkyl, C3-8 cycloalkyl, linear or branched C2-10 alkenyl or C3-10 cycloalkenyl, Ph or C1-10 alkyl-substituted Ph, etc.; R1 = -COOR4 with R4 being H, linear or branched C1-10 alkyl, alkyl with 1-3 substituting groups selected from oxyl, halogen, C1-10 alkyl, alkanoyloxyl, aryloxyl, etc., C3-8 cycloalkyls, alkys substituted with 1-3 hetero atoms, arylalkyls, etc., or -CONR5R6 with R5and R6 being H, linear or branched C-10 alkyls, alkyls substituted with 1-3 groups selected from hydroxyl, amino, C1-10 alkylamino, oxyl, halogens, etc., C3-8 cycloalkyls, C1-10 alkyls substituted with 1-3 heteroatoms, arylalkyls, etc.). The title preparation includes subjecting Neogambogic acid to condensation, etherification, reduction, and acylation to obtain compds. I, and carrying out addition with hydrogen peroxide to the C9 C10 bond of Neogambogic acid in the presence of a base, or carrying out 1,4-addition with organocopper reagent to the C9 C10 bond to obtain compound derivs. Title compds. can be applied in treating cancer.

IT 905560-79-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of Neogambogic acid derivs. as antitumor agent)

RN 905560-79-4 CAPLUS

CN 2-Butenamide, N-(2-ethoxyethyl)-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7,10,11-hexahydro-8,9-dihydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,9H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-methyl-, (2Z)- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown. Currently available stereo shown.

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588556 CAPLUS <<LOGINID::20090326>>

DOCUMENT NUMBER: 143:115395

TITLE: Preparation of derivatives of gambogic acid and analogs as activators of caspases and inducers of

apoptosis

Enalish

INVENTOR(S): Cai, Sui Xiong; Jiang, Songchun; Zhang, Han-Zhong

PATENT ASSIGNEE(S): Cytovia, Inc., USA SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

GI

PAT	ENT :	NO.			KIN	D	DATE		APPLICATION NO.					D	DATE			
						_												
	2005				A2		2005	0707	707 WO 2004-US42292				20041217					
WO	2005	0606	63		A3		2005	1222										
	W:						AU,											
		CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,	
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	SM
	RW:						MW,											
		ΑZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
							GR,											
							BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	
			NE,															
US	2007	0093	456		A1	A1 20070426 US 2006-580263					0060							
PRIORITY	APP	LN.	INFO	. :			US 2003-530256P P 20031218				218							
	WO 2004-US42292 W 20041217																	
OTHER SOURCE(S): CASREACT 143:115395																		

- \* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT \*
- AB The present invention is directed to novel derivs. of gambogic acid (I) and analogs thereof. Thus, 2-(Dimethylamino)ethyl gambogate (II) was prepared from I via esterification with CICH2CH2NNMe2-HCI in the

presence of KI and Cs2CO4. The present invention also relates to the discovery that novel derives, of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. The bioactivity of II was determined (caspase cascade activation ECSO = 676 nM vs. T-470 and ECSO = 1041 nM vs. DLD breast cancer cells; cell proliferation inhibition GISO = 187 nM (vs. T-47D), GISO = 183 nM (vs. DLD), GISO = 101 nM (vs. MX-1), GISO = 180 nM (vs. SW62O), GISO = 184 nM (vs. HEXP39H)].

IT 857500-91-5P, N-[3-(4-Methylpiperazin-1-y1)propyl]gambogamide 857500-92-6P, N-[3-(Morpholin-4-y1)propyl]gambogamide 857501-27-0P, N-(4-Azido-2,3-5,6-tetrafluorobenzyl)gambogamide 857501-29-2P, N-[(S)-1,2-Dicarboxyethyl]gambogamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses) (preparation of derivs. of gambogic acid and analogs as activators of

caspases and inducers of apoptosis)
RN 857500-91-5 CAPLUS

CN

2-Butenamide, 2-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4[(1R, 3aS, 5S, 1R, 14aS)-3a, 4, 5, 7-tetrahydro-8-hydroxy-3, 3, 11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7, 15-dioxo-1, 5-methano1H, 3H, 11H-furo[3, 4-q]pyrano[3, 2-b]xanthen-1-yl]-, (2Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 1-B

RN 857500-92-6 CAPLUS

CN 2-Butenamide, 2-methyl-N-[3-(4-morpholinyl)propyl]-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

PAGE 1-B

RN 857501-27-0 CAPLUS

CN 2-Butenamide, N-[(4-azido-2,3,5,6-tetrafluorophenyl)methyl]-2-methyl-4[(1R,3a8,58,1R,14a8)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano1H,3H,1HF-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, (22)- (CA INDEX NAME)

\_N3

~ E

RN 857501-29-2 CAPLUS

CN L-Aspartic acid, N-[(2Z)-2-methyl-1-oxo-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7 tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4 methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1H,3H,1H-furo[3,4 g)pyrano[3,2-b]xanthen-1-yl]-2-buten-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.42	61.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.46	-3.28

FILE 'REGISTRY' ENTERED AT 16:54:09 ON 26 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the  ${\tt ZIC/VINITI}$  data file provided by  ${\tt InfoChem.}$ 

```
STRUCTURE FILE UPDATES: 25 MAR 2009 HIGHEST RN 1127021-37-7
DICTIONARY FILE UPDATES: 25 MAR 2009 HIGHEST RN 1127021-37-7
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s morellinat? L6 1 MORELLINAT?

=> d 16

- L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
- RN 14916-03-1 REGISTRY
- ED Entered STN: 16 Nov 1984
- CN Copper, bis(deoxymorellinato-07,08)- (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES:
- CN Morellin, deoxy-, Cu deriv. (7CI)
- MF C66 H74 Cu O12
- CI CCS
- LC STN Files: CA, CAPLUS

PAGE 1-A

CH2-CH-CMe2

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>